On May 30, 2017 Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development of novel therapies designed to activate a patient’s immune system against cancer, reported that it will present a poster from the Phase II trial evaluating HS-410 (vesigenurtacel-L) in combination with standard of care, Bacillus Calmette-Guérin (BCG), in the treatment of non-muscle invasive bladder cancer (NMIBC) at the 2017 ASCO (Free ASCO Whitepaper) (American Association of Clinical Oncologists) Annual Meeting at McCormick Place in Chicago, Illinois on Sunday, June 4th, 2017 (Press release, Heat Biologics, MAY 30, 2017, View Source [SID1234519321]). Schedule your 30 min Free 1stOncology Demo! Poster Presentation Details
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Immune response results from vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase 2 trial in patients with non-muscle invasive bladder cancer (NMIBC).
Date and Time: Sunday, June 4, 8:00 AM to 11:30 AM
Poster Number: 209